Similarly, HR+HER2− tumors with ER+ scores of 10% and above as assessed by IHC were also reported to have inadequate downstream ER activity, categorizing them as a poor prognostic group endorsing the biological heterogeneity associated with the HR+ breast cancer subtype [32,36]. This evidence concerns the gene ESR1 and breast cancer.